The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of CBDCA + PEM + pembrolizumab in elderly (=75 yrs) patients with advanced non-Sq, NSCLC.
 
Hiroaki Akamatsu
Honoraria - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Janssen; Kyowa Kirin International; Lilly; MSD; Nippon Kayaku; Novartis; Novocure; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; GlaxoSmithKline; Janssen; Sandoz
Research Funding - Amgen (Inst); Chugai Pharma (Inst); Novartis (Inst)
 
Kazuhiro Negoro
No Relationships to Disclose
 
Ryota Ueda
No Relationships to Disclose
 
Keita Nakaguchi
No Relationships to Disclose
 
Yuhei Harutani
No Relationships to Disclose
 
Eri Takase
No Relationships to Disclose
 
Katsuyuki Furuta
No Relationships to Disclose
 
Yusuke Murakami
No Relationships to Disclose
 
Eriko Murakami
No Relationships to Disclose
 
Atsushi Hayata
No Relationships to Disclose
 
Ke Wan
No Relationships to Disclose
 
Toshio Shimokawa
No Relationships to Disclose
 
Kuninobu Kanai
No Relationships to Disclose
 
Nobuyuki Yamamoto
Honoraria - Abbvie; Acuuray; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Janssen; Kyorin; Kyowa Kirin International; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; MSD; Novartis; Ono Pharmaceutical
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); EPS Corporation (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); Mebix (Inst); Medpace (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Prime-R (Inst); Syneos Health (Inst)